Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 14th, 2026

LECO_Weekly-Healthcare-News_9-14-2026Download

Healthcare Weekly News and Deals –Sept 14th, 2026

  1. Addus HomeCare (NASD: ADUS) to Acquire Advent International–Backed AccentCare’s Personal Care Division for Approximately $275 Million Advent International’s AccentCare is selling only the non-New York personal-care book; hospice and skilled home health stay with the seller. Addus, a scaled non-franchise home-care operator listed on Nasdaq, is paying about $275 million after customary adjustments and funding the check with revolver and cash. The assets serve roughly 13,700 patients a day across 10 states and should add about $280 million of annualized personal-care revenue, a 19% lift to Addus’s base. Density is heaviest in Texas, Illinois, California and Arizona, with additional volume in Colorado, Georgia, Minnesota, Pennsylvania, Tennessee and Washington. The purchase extends Addus’s Medicaid-heavy personal-care footprint rather than buying hospice or Medicare home health.  (Link)
  2. Axogen (NASD: AXGN) to Acquire BioCircuit Technologies for $200 Million in Cash Axogen is paying $200 million cash for BioCircuit, with $1 million held back for the post-close true-up, and is funding the check with a concurrent $208.7 million common-stock offering. The prize is NerveTape, the first FDA-cleared sutureless device for peripheral nerve repair, plus ConformaWrap. BioCircuit did about $11 million of revenue in 2025 and is running at roughly $24 million on more than 14,000 implants across 400-plus hospital and ASC accounts. Convertible notes convert and an unrelated electronics R&D unit is spun out before closing. Management expects year-one accretion to growth, adjusted EBITDA margin and adjusted EPS while remaining free-cash-flow positive.  (Link)
  3. COSCIENS Biopharma (TSX: CSCI) Acquires Nualtis from AtaiBeckley (NASD: ATAI) for $15 Million Plus Earnouts COSCIENS is buying Montreal oral-thin-film CDMO Nualtis, formerly IntelGenx, from AtaiBeckley for $15 million plus four earnouts equal to 10% of adjusted EBITDA in 2027–2030. Nine million dollars was paid at close; $6 million is deferred six months. The plant is FDA- and Health Canada-inspected and runs VersaFilm for human therapeutics and VetaFilm for veterinary use, with an existing pipeline and pharma partnerships. A concurrent first tranche of unsecured convertibles raised about $6 million toward a $20 million cap and funded the closing check. For a small TSX-listed ingredients company, the deal is a way to own a purpose-built film platform rather than build one.  (Link)
  4. Patient Square–Backed Hanger to Acquire AEA’s Numotion; Combined Company to Be Called Hanger Numotion Patient Square is putting two mobility platforms under one roof in a cash purchase. Hanger contributes 925 U.S. orthotic and prosthetic clinics; AEA Investors’ Numotion contributes more than 200 complex-rehab and mobility sites in the United States and Canada. Combined they will serve more than 1.5 million patients a year and keep both brands and clinical operations. Numotion CEO Mike Swinford, in the seat since 2014 after two decades at GE including GE Healthcare Services, will run the combined company as Hanger Numotion; Pete Stoy steps aside. The combination is PE-backed specialty-provider consolidation across complementary mobility verticals, not a single-clinic tuck-in.  (Link)
  5. Apple (NASD: AAPL) Acquires Berkeley Brain-Sensing Startup Sonera Apple has bought Sonera, a Berkeley company that builds chip-scale magnetic sensors to read neural and muscle activity without implants or skin-contact electrodes. Co-founders Nishita Deka and Dominic Labanowski started the firm in 2018 out of UC Berkeley; it later raised about $20 million, including an $11 million 2023 seed, and marketed an S1 biomagnetic chip for muscle sensing, prosthetics and wearables. Magnetic readout is meant to avoid the skull-dampening that limits electrical EEG. Apple has not said what the team will work on. Outside write-ups point at Watch-class neuromuscular monitoring and hands-free accessibility; those uses are inferred, not confirmed. (Link)
  6. Labcorp (NYSE: LH) Acquires Great Point Partners’ MLM Medical Labs Great Point Partners is exiting MLM Medical Labs, the central- and specialty-lab it built in the United States, Germany and South Africa. Labcorp is folding the network in so it owns laboratories on four continents — North America, Europe, Asia and Africa — including the first CAP-accredited central lab on the African continent. MLM adds biomarker and specialty capacity for multinational trial work that Labcorp previously covered through a mix of owned sites and partners. The industrial logic is one operator, one scientific and regulatory stack, on global protocols rather than a patchwork of affiliate labs.  (Link)
  7. General Catalyst– and CVS Health Ventures–Backed H1 Acquires Defacto Health to Add Provider-Network Intelligence H1, the physician-data platform backed by General Catalyst and more recently CVS Health Ventures, is buying Defacto Health, a specialist in payer-network and directory intelligence. Defacto maps which clinicians sit in which networks and which plans they accept — the data health plans use to test directory accuracy, isolate error clusters and benchmark access. It was already a data partner. Co-founders Ron Urwongse and Tarun J. Theogaraj, both formerly of CAQH, join H1 and will keep running the product inside the Doctor Graph rather than as a standalone brand. The buy sits against ongoing CMS and plan pressure on directory accuracy as provider and network data change continuously.  (Link)
  8. Eir Partners Acquires Accumulus Technologies, the Life-Sciences Regulatory Cloud Platform Eir Partners is buying Accumulus Technologies, a San Francisco regulatory-cloud platform that connects more than 75 agencies to life-sciences sponsors. The product is built for multi-agency review rather than point-to-point filings and already has live Veeva RIM connectivity. Accumulus was spun out of nonprofit Accumulus Synergy in 2025 so it could raise capital and sell commercially; CEO Francisco Nogueira stays. Eir, a healthcare software firm, is treating the asset as a category platform at the intersection of life sciences, technology and global regulation rather than a point tool for a single agency workflow.  (Link)
  9. 1315 Capital Buys Argonaut’s Life Sciences and Diagnostics Unit; Business Relaunches as Aluris Sciences 1315 Capital is buying only Argonaut’s life-sciences and diagnostics manufacturing unit and relaunching it as Aluris Sciences. Telegraph Hill Partners, New Vale Capital and management keep the Carlsbad aseptic fill-finish CDMO. Aluris runs formulation through commercial production for diagnostics, life-sciences and combination-product customers and will operate independently; staff and resources were already largely separate, so live programs do not move. Sale proceeds recycle into Argonaut’s fill-finish capacity. The structure is a clean carve-out rather than a whole-company sale of a dual-vertical CDMO.  (Link)
  10. SK Capital–Backed Precera Medical Acquires Additive Metal Services Precera Medical, the four-plant orthopedic and interventional OEM SK Capital carved out of LISI Medical in November 2025, is adding Additive Metal Services of Port Huron. The shop brings metal-injection molding and sinter-based additive manufacturing for precision components — robotic-surgery end effectors and distal interventional-catheter parts among the named uses. Precera already runs design, prototyping, precision machining, micro-feature work, automation and finished-device assembly across Minnesota and France. Customer programs and tooling stay. The add-on is process-capability adjacency on a new platform, not a new end-market.  (Link)
  11. Avesi Partners–Backed Danforth Health Acquires Ambit RD Avesi Partners’ Danforth Health is buying Ambit RD, a rare- and specialty-disease shop that sells commercial strategy, advanced analytics and AI-assisted patient identification into biopharma. CEO Rob Sederman and CCO Ned Kitfield stay. Ambit is the latest add onto a platform that has already rolled up Asymmetry Group, PharmaDirections, VPMR, Advyzom, Benchworks, Elite BioPharma Consulting and Argot Partners. The thesis is a single commercialization backbone from clinic through launch rather than another standalone consultancy sitting beside the last one. Rare-disease commercial work is one of the few remaining fee pools that still pays for specialist analytics.  (Link)
  12. RiverGlade Capital Makes Platform Investment in Senior Living Residences RiverGlade Capital is backing Senior Living Residences, the Braintree operator of 24 independent living, assisted living and memory-support communities across New England and the broader Northeast. Founder Robert Larkin and CEO Tadd Clelland stay; the SLR name stays. The company has run service-enriched buildings for nearly four decades and includes the Compass Memory Support Neighborhoods line. RiverGlade is a healthcare PE firm that typically partners with founder-led lower-middle-market operators and funds people, operations and both organic and acquired growth. No price was printed. The check is meant to keep expanding the Northeast book without changing the operating identity. The transaction closed in July; this is the first public write-up.  (Link)
  13. Latticework Capital–Backed Beacon Behavioral Partners Acquires Albaron’s Prime Psychiatry Latticework Capital’s Beacon Behavioral Partners is buying Prime Psychiatry from Albaron Partners, which backed founder Dr. Efosa Airuehia in 2022. Prime is outpatient and interventional psychiatry — medication management plus TMS and Spravato — for children, adolescents and adults across Dallas–Fort Worth and Austin. The clinics join a national behavioral platform that has been adding partner practices across the Southeast and Midwest while leaving local brands intact. Local physicians stay. The sale is a sponsor-to-sponsor handoff of a regional interventional-psychiatry density play rather than a de novo clinic build.  (Link)
  14. Santé Ventures–Backed Jaguar LAA Acquires Johnson & Johnson (NYSE: JNJ) Laminar Program Assets Santé Ventures formed Jaguar LAA with members of the Laminar team to take Johnson & Johnson’s left-atrial-appendage program out of a strategic and finish development as an independent company. The asset is a catheter-based LAA-closure approach aimed at stroke-risk reduction in non-valvular atrial fibrillation and designed to leave minimal hardware in the left atrium. Key program assets and the originating engineers move together. The structure is a classic medtech carve-out plus NewCo financing rather than a license back to the seller.  (Link)
  15. InTandem-Backed Ivy Fertility Acquires Santa Barbara Fertility Center InTandem Capital’s Ivy Fertility is adding Santa Barbara Fertility Center, opened in 2008 by reproductive endocrinologist Rene Allen after a USC fellowship. Allen stays and continues to practice. The same announcement adds five other physicians across Ivy’s network and a build-out in male fertility. Local brand is retained. Ivy is already a multi-state IVF platform; Santa Barbara is a coastal California density add with an existing physician and lab book, not a 100%-owner partnership that leaves control unchanged.  (Link)
  16. LongueVue-Backed Summit / Pinnacle Acquires Dallas Research Institute LongueVue Capital’s Summit / Pinnacle site network is buying Dallas Research Institute, a single-site DFW unit opened in 2024 with the late hepatologist Dr. Stephen Harrison and focused on MASLD, MASH and obesity trials. Principal investigator Dr. Pedro Castillo Jr. stays. The buyer already runs 15 owned U.S. sites plus 110-plus partner sites in eight countries, with IRO, recruitment, medical-communications and early-phase CRO affiliates under the same roof. The add is metabolic-site density in a high-enrolling metro rather than a new therapeutic vertical.  (Link)
  17. VSS-Backed Olympus Cosmetic Group Acquires Gallaher Plastic Surgery & Med Spa VSS-backed Olympus Cosmetic Group is buying Gallaher Plastic Surgery & Med Spa, its first Tennessee practice and the entry into Knoxville. Dr. Tom Gallaher stays under a physician-led model and the local brand is being kept. Olympus is a surgeon-founded aesthetics platform assembling plastics and med-spa density market by market rather than a roll-up that rebrands every site on day one. The add-on is a local-brand-preserved clinic purchase into an unpenetrated MSA, not a new platform launch.  (Link)
  18. Frazier-Backed LUX Infusion Acquires Two Northeast Ambulatory Infusion Centers Frazier Healthcare’s LUX Infusion is buying two Northeast ambulatory infusion centers: South Jersey Pediatric and Adult Infusion Center in Cherry Hill, N.J., and Northeast Infusion Therapy in Latham, N.Y. The purchases are separate from the August Infuse IQ deal. LUX is a clinician-led home-plus-center platform after the BioMatrix rebrand. The two sites bring chair capacity and existing physician-referral books in two new Northeast MSAs, which is the density the platform needs if home infusion and AIC are going to sit on the same operating system.  (Link)
  19. Altas Partners and L Catterton Agree to Acquire Fullscript from HGGC Altas Partners and L Catterton are buying a majority stake in Fullscript from HGGC and Snapdragon Capital Partners. The Ottawa platform, founded in 2011, sells practitioners an integrated stack of diagnostics, treatment planning and dispensed supplements and already cites more than 135,000 clinicians, about 10 million patients a year and $1 billion-plus of revenue. HGGC and Snapdragon put $240 million in during 2021, later added Rupa Health for labs, and used a Leonard Green continuation vehicle in 2025. The new sponsors are taking majority control to fund further clinical-tool and North American expansion.  (Link)
  20. Revvity (NYSE: RVTY) to Acquire France’s Human Cell Design Revvity is buying Human Cell Design, a French specialist in human pancreatic beta-cell models. The flagship line is EndoC-βH5, sold with specialized media, reagents, preclinical services and the NatLine cell-line platform for diabetes, obesity and other metabolic work, including GLP-1 and GPCR programs. Revvity is treating the company as a reagents tuck-in that sits next to HTRF, AlphaLISA, ATPlite and high-content screening rather than a new instruments franchise. Human-relevant cell models have become a procurement item for metabolic and incretin discovery groups that want to reduce animal-only screening.  (Link)
  21. Novo Holdings Makes Minority Investment in China’s ForYou Medical; GL Capital Remains Majority Novo Holdings is taking a minority stake in ForYou Medical; GL Capital remains majority owner. The Huizhou company is a CDMO focused on advanced wound-care manufacturing for global device customers rather than a branded finished-goods play. Novo Holdings’ China head framed the check as the firm’s first China medtech ticket and part of a larger Asia ramp in both check size and local team. The industrial logic is specialized converting capacity plus China-to-global customer access, not a control deal or a domestic hospital chain.  (Link)
  22. Nvidia- and Health System–Backed Artisight Acquires TMG Global Artisight, the Nvidia- and health-system-backed smart-hospital vendor, is buying TMG Global, a healthcare infrastructure and site-readiness shop that runs large technology deployments. The team comes in-house so health systems have one accountable path from clinical-space and MDF/IDF surveys through hardware staging, install, validation, training and Day-1 support. Artisight’s platform uses computer vision and ambient sensing to run operating rooms and inpatient units; the bottleneck has been deployment, not the model. The purchase is operational capacity for enterprise rollouts, not a new clinical product.  (Link)
  23. Sanofi (NASD: SNY) and Braun Family–Owned Cheplapharm to Form Mature-Medicines Partnership Sanofi is moving a tail of 20 mature medicines and three plants to Cheplapharm, the German family-owned established-products company controlled by the Braun family, and taking a 26.4% equity stake in return. The plants are Csanyikvölgy in Hungary (about 400 employees), Jurong in Singapore (about 100) and Ploërmel in France (about 65), and they include manufacturing for Lovenox/Clexane. The two sides have collaborated since 2014. Commercial transfer is planned to start in early 2027, then the sites, subject to works-council consultation and regulatory approvals. Structure is a partnership and minority stake, not a signed control sale of Cheplapharm.  (Link)

Venture Deals and Other

  1. Forus Raises $150 Million Series C at a $3 Billion Valuation, Led by Bain Capital Ventures Bain Capital Ventures led a $150 million Series C in Forus at a $3 billion valuation, four months after a $160 million Series B. Every existing institution re-upped, including Thrive, General Catalyst, Accel, Redpoint, BoxGroup and Pear; cumulative capital now exceeds $300 million. Forus, formerly Tandem, builds an AI agent per prescription that sits between the physician, payer, pharmacy and manufacturer to clear access work and is free to doctors and patients. Coverage is all 50 states and about 85% of U.S. residential ZIP codes. Proceeds go to specialty expansion, more agents and commercial headcount.  (Link)
  2. BrainChild Bio Closes $116 Million Series A BrainChild Bio raised $116 million in a Series A led by a family fund and foundation aligned with the pediatric-oncology mission; Seattle Children’s, the original investor, and WRF Capital joined. Proceeds fund ILLUMINATE, the Phase 2 pivotal trial of BCB-276, a B7-H3 CAR-T, in diffuse intrinsic pontine glioma, and push triple-target construct BCB-214 toward first-in-human glioblastoma work. The platform is licensed from Seattle Children’s. Steven Brugger is CEO. DIPG remains a category with almost no approved options, which is why a mission-aligned family check can lead a round of this size.  (Link)
  3. TwoStep Therapeutics Raises Oversubscribed $62.5 Million Series A; FDA Clears TS-104 IND Insight Partners and Medical Excellence Capital led an oversubscribed $62.5 million Series A in TwoStep Therapeutics; Pfizer Ventures and Merck KGaA’s M Ventures co-led, with NFX, 2048 Ventures and Stanford joining. Cumulative capital is $71.2 million. The company’s peptide-drug conjugate binds five tumor-associated integrins rather than a single antigen, a design aimed at tumors that lack a clean one-target profile. FDA has cleared the TS-104 IND; Phase 1 enrollment is expected later this year. Proceeds also fund a radioligand program and next-generation peptide conjugates.  (Link)
  4. Kura Oncology (NASD: KURA) Launches Caspian Therapeutics with $50 Million Series A Led by BVF; Eli Lilly (NYSE: LLY) Participates Kura Oncology launched Caspian Therapeutics with a $50 million Series A led by BVF Partners. Kura contributed menin-inhibitor IP including KO-7246, invested $4.3 million and keeps about 49%. Eli Lilly and the T1D Fund joined, alongside Invus, Montanova and Kura management. Proceeds take KO-7246 into Type 1 and Type 2 diabetes proof-of-concept and fund a second menin asset for broader cardiometabolic use; oncology stays at the parent. Kura CEO Troy Wilson is executive chair; Rob Spencer is president and COO. Phase 1 is targeted by the end of 2027.  (Link)
  5. Implicity Raises $40 Million Growth Round Led by IRIS and Five Arrows IRIS and Rothschild & Co’s Five Arrows led a $40 million growth round in Implicity. The Cambridge and Paris company already covers more than 250 medical centers and monitors 120,000-plus patients a day across the United States, France and Germany. The platform is FDA-cleared AI sitting on connected pacemakers, defibrillators and implantable loop recorders; published real-world data cite a 26% mortality reduction and a 4% drop in hospitalizations versus conventional remote monitoring. Proceeds go to U.S. commercial hiring, U.S.-specific product work and further AI, including heart-failure prediction.  (Link)
  6. Epsilon Health Emerges from Stealth with $27.6 Million Led by AlleyCorp AlleyCorp led a $27.6 million stealth round in Epsilon Health; Uncork Capital, Renegade Partners, SemperVirens and Jack Altman joined. Epsilon is an AI-native radiology practice — physicians plus models — not a point-solution vendor selling into someone else’s group. It already serves more than 250,000 patients, reads 2,500-plus studies a day, and handles more than half the volume at one large outpatient imaging chain. Management says it is on track for about 1% of daily U.S. X-rays this year. Head of machine learning is ex-DeepMind; the CMO is former Envision Radiology CMO.  (Link)
  7. GenHealth.ai Raises $16.5 Million Series A Led by Flare Capital Partners Flare Capital Partners led a $16.5 million Series A in GenHealth.ai. Craft Ventures and Obvious Ventures re-upped; Eniac, InHealth Ventures, Epsilon Health Investors and ARTIS came in. Cumulative capital is about $30 million after a 2023 seed. The Boston company, spun out of 1upHealth, deploys agents inside existing EHRs and payer systems for intake, eligibility, prior authorization, billing, denials and appeals rather than selling another system of record. Management cites a 34% revenue lift and up to 80% admin-cost reduction; Guidehealth reports 4x productivity on intake and prior auth.  (Link)
  8. UrgentIQ Raises $15 Million Series A Led by Five Elms Capital Five Elms Capital, a vertical-software growth shop with more than $3 billion under management, led a $15 million Series A in UrgentIQ. The product is an AI-native EMR and operating system built for urgent care rather than a hospital or primary-care fork. Proceeds fund a native billing module, AI documentation and coding, live insurance verification and an AI checkout agent, plus commercial headcount. Founder Nat Gibbs is building against a market that still runs on hospital-grade EMRs never designed for high-throughput episodic visits. Earlier seed capital was not a named institutional growth round.  (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 1st, 2026

LECO_Weekly-Healthcare-News_6-1-2026Download
  1. Healthcare Capital Markets & Innovation Summit (HCMIS 2026) — Day 1 Recap | Theme: “Longevity in Healthcare & Capital Investment” Day 1 of HCMIS 2026 brought together healthcare operators, investors, lenders, innovators, entrepreneurs, and advisors in Columbus, Ohio. The day opened with insights on healthcare deal activity, capital flows, and the state of healthcare credit markets, with a consistent theme: regardless of market conditions, healthcare organizations must continue to innovate, invest, and execute to create long-term value. A fireside discussion with Daryl Tol, President & CEO of HATCo, explored the transformation of health systems and the growing importance of strategic partnerships, innovation platforms, and new operating models. Key discussion tracks included Healthcare Lending & Private Credit, AI & Value-Based Care, Behavioral Health & Health System Innovation, and Healthcare Consumerization. One featured highlight was the “Longevity: Scaling for Healthspan and Lifespan” panel covering preventive care, diagnostics, AI, GLP-1 therapies, and personalized medicine, followed by a lunchtime panel on Longevity as an emerging investment opportunity. The afternoon featured discussions on healthcare M&A, AI in Transactions, Rural Health Innovation, and Strategic Partnerships. New for 2026 was the inaugural Pitch Competition, featuring 13 finalists screened using HDIG’s AI-powered innovation assessment tools, competing for cash prizes, professional services, investment opportunities, and the Blue Jacket Award. (Link)
  2. Eli Lilly (NYSE: LLY) agreed to acquire Seattle-area clinical-stage biotech Curevo Vaccine for up to $1.5 billion in cash — an upfront payment plus a milestone payment — to advance Phase 3-ready next-generation shingles vaccine candidate amezosvatein; Lilly simultaneously announced two additional vaccine acquisitions the same week, bringing total combined consideration to up to ~$3.83 billion Eli Lilly announced on May 26, 2026 agreements to acquire three private vaccine companies simultaneously: Curevo, Inc. (up to $1.5B), LimmaTech Biologics AG (up to $780M), and Vaccine Company, Inc. ($1.55B). Curevo’s lead program, amezosvatein, is a Phase 3-ready adjuvanted subunit shingles vaccine designed to match GSK’s Shingrix on efficacy while reducing side effects by 50%+ in head-to-head Phase 2 data. LimmaTech Biologics is developing vaccines against antimicrobial-resistant bacterial pathogens including S. aureus (LTB-SA7, Phase 1), gonorrhea, and chlamydia. Vaccine Company develops nanoparticle-based vaccines targeting viral diseases. The triple deal signals Lilly’s strategic push into infectious disease prevention using GLP-1 profits, noting common infections are increasingly linked to downstream neurological disease, cancer, and infertility. (Link)
  3. Pfizer (NYSE: PFE) and Suzhou, China-based Innovent Biologics (HK: 01801) entered a global strategic licensing and collaboration agreement for 12 early-stage oncology programs — antibody-drug conjugates and multispecific antibodies — valued at up to $10.5 billion, with $650 million upfront Pfizer and Innovent Biologics announced on May 28, 2026 a strategic global licensing and collaboration agreement covering 12 early-stage cancer medicine programs for up to $10.5 billion. Innovent receives $650 million upfront plus up to $9.85 billion in milestones and double-digit royalties on approved products. The portfolio spans ADCs with novel differentiated payloads and multispecific antibodies with unique immune-engaging designs — eight programs from Innovent, four proposed by Pfizer. The deal is structured in three buckets with varying exclusivity and cost-sharing; Innovent leads Phase 1 trials before Pfizer takes over global development. Innovent shares rose 10%+ in Hong Kong on announcement. One of the largest oncology licensing transactions of 2026, highlighting surging U.S. pharma appetite for Chinese biotech innovation despite geopolitical pressures. (Link)
  4. HCA Healthcare (NYSE: HCA) agreed to acquire The College of Health Care Professions (CHCP), a Texas-based allied health educator with 8,000+ students annually across 10 campuses, to vertically integrate its clinical workforce pipeline HCA Healthcare announced on May 27, 2026 a definitive agreement to acquire The College of Health Care Professions (CHCP), one of the largest allied healthcare training institutions in Texas. CHCP educates more than 8,000 students annually across 10 Texas campuses and online in medical assisting, surgical technology, medical imaging, and allied health programs, and provides continuing education nationwide through its Medical Technology Management Institute. The deal directly addresses the national clinical labor shortage pressuring hospital margins industry-wide. HCA and CHCP have partnered for over a decade through clinical rotations and career placement. Chancellor and CEO Eric Bing will remain to lead CHCP. (Link)
  5. Tractor Supply Company (NASD: TSCO) acquired VIP Petcare veterinary services — the largest provider of mobile veterinary care in the U.S., operating clinics in ~2,700 retail locations across 39 states — from Bansk Group’s PetIQ, bringing vet services in-house across its rural lifestyle retail footprint Tractor Supply Company (NASD: TSCO), the largest rural lifestyle retailer in the U.S., announced on May 28, 2026 it has acquired the veterinary services business VIP Petcare (operating as VIP Petcare and PetVet) from PetIQ, a Bansk Group company. VIP Petcare is the largest provider of mobile veterinary care in the United States, operating community clinics in approximately 2,700 retail locations — including 1,700 locations — across 39 states and serving more than one million pets annually. Bringing VIP Petcare in-house deepens Tractor Supply’s omnichannel pet health platform alongside its Petsense by Tractor Supply stores and Allivet digital pharmacy. (Link)
  6. Mesquite, Texas-based Ernest Health signed a definitive agreement to acquire Reunion Rehabilitation Hospitals — a seven-hospital network across Arizona, Colorado, Texas, and Florida — expanding its footprint from 38 to 45 rehab hospitals Ernest Health, a national post-acute rehabilitation operator, signed a definitive agreement to acquire Reunion Rehabilitation Hospitals, a network of seven medical rehabilitation hospitals in Arizona, Colorado, Texas, and Florida. The deal lifts Ernest’s network from 38 to 45 rehabilitation hospitals nationwide. President and CEO Jake Socha said Reunion’s mission and culture align with Ernest’s locally led hospital model, and the transition will proceed over coming months with no disruption to operations; Reunion employees can remain and join Ernest. (Link)
  7. AI-driven healthcare-engagement platform Swoop acquired prescription-management platform Nimble (NimbleRx) — which serves 16 million patients across independent pharmacies in all 50 states — to add prescription fulfillment and pharmacy connectivity Swoop, an AI-driven, privacy-compliant healthcare marketing platform for life sciences, acquired Nimble (also known as NimbleRx), a prescription-management platform spanning independent pharmacies in all 50 states and enabling 16 million patients to fill, refill, pay for, and manage prescriptions. The combined offering, branded SwoopRx by Nimble, adds prescription fulfillment, pharmacy connectivity, and adherence tools to Swoop’s portfolio. CEO Ron Elwell said the deal extends Swoop “beyond engagement to impact,” while Nimble founder/CEO Talha Sattar emphasized closing the gap between prescription and adherence. Financial terms were not disclosed. The acquisition follows Swoop’s earlier purchase of MyHealthTeam. (Link)
  8. Chicago-based private credit manager Monroe Capital acted as lead arranger and administrative agent on a senior credit facility backing private equity sponsor Warburg Pincus’ investment in Waco, Texas-based home-based care provider Cornerstone Caregiving (terms undisclosed). Monroe Capital LLC arranged and administered a senior credit facility to support private equity firm Warburg Pincus’ investment in Cornerstone Caregiving, a Waco, Texas home-based care provider founded in 2020 that offers hospice, home care, palliative care, and senior services (including Alzheimer’s and dementia care) across hundreds of U.S. locations; financial terms were not disclosed. Monroe framed the deal as continued PE appetite for non-acute, lower-cost care delivery as hospitals and insurers shift volume out of institutional settings. Warburg Pincus, founded in 1971, has invested over $130 billion across 1,100-plus companies; the financing adds to Chicago-based Monroe’s growing healthcare-services private credit portfolio. (Link)
  9. Cleveland, Ohio- and Dallas-based private equity firm Align Capital Partners (ACP) acquired Heritage Imaging, a mobile diagnostic imaging provider serving hospitals across 14 states, as a new platform investment Align Capital Partners (ACP), a lower-middle-market PE firm headquartered in Cleveland, Ohio (Shaker Heights) and Dallas with $2.1 billion in committed capital, acquired Heritage Imaging as its next platform. Founded in 1989, Heritage provides fully staffed mobile diagnostic imaging — PET/CT, MRI, nuclear medicine, ultrasound and echocardiography — to hospitals across 14 states, focusing on rural and underserved markets. CEO Dr. Steve Coppess and the management team stay on. ACP’s Rob Langley led the deal and plans further M&A in outsourced imaging; Heritage has closed three add-ons since 2024. (Link)
  10. Baltimore, Maryland-based Procare Ambulance entered a strategic partnership with Prodos Capital and Manolin Investment Group — with growth capital from Tecum Capital, Genesis Park Capital, and SharpVue Capital — to expand its Mid-Atlantic emergency and non-emergency interfacility transport and Mobile Integrated Health platform Procare Ambulance of Maryland, a Baltimore-based provider of non-emergency and emergency interfacility transportation (IFT) services serving the Maryland and Washington, D.C. markets with recent expansion into Virginia, entered a strategic partnership with Prodos Capital and Manolin Investment Group on June 1, 2026. Tecum Capital, Genesis Park Capital, and SharpVue Capital provided growth capital to support the partnership. Procare delivers Basic Life Support, Advanced Life Support, Specialty and Critical Care Transport, Mobile Integrated Health (MIH), and medical standby services to a roster of healthcare institutions across the Mid-Atlantic. Founder Debbie Ailiff and CEO Mark Bucholtz will remain to lead the business; the partnership will support geographic expansion into Virginia, development of the MIH program, and investment in workforce and fleet. (Link)
  11. New Hyde Park, NY-based Premier Care Dental Management (PCDM) acquired Brett Pelok, DDS & Associates, a general dental practice in Toledo, Ohio led by Ohio Dental Association President-Elect Dr. Brett Pelok, deepening PCDM’s Ohio presence Premier Care Dental Management (PCDM), a multi-state Dental Clinical Organization, acquired Brett Pelok, DDS & Associates, a general dental practice in Toledo, Ohio. The practice is owned by Dr. Brett Pelok, President-Elect of the Ohio Dental Association, who will continue leading clinical care post-transaction. CEO and founder Dr. Scott Asnis said the deal supports PCDM’s growth while letting the practice keep its identity and clinical leadership. PCDM operates across NY, CT, NJ, PA, OH, NH, MA, and RI. (Link)
  12. Chicago-based, doctor-owned PE platform Phase 1 Equity added a multi-site orthodontic practice in Texas — its third practice acquisition of 2026 — bringing the network to 21 doctors and 31 locations Phase 1 Equity, a Chicago-based doctor-owned, doctor-led PE platform for orthodontists and pediatric dentists, added another multi-site orthodontic practice in Texas. This marks its third practice addition of 2026, its third in Texas, its 21st affiliated doctor, and lifts total locations to 31. CEO Mike Rice cited continued momentum as more doctors recognize the platform’s value. Doctors retain clinical control while gaining shared services and PE-style resources. (Link)
  13. MorningStar Senior Living recapitalized its 112-unit Houston assisted-living and memory-care community, River Oaks, with TPG Angelo Gordon U.S. Real Estate, retaining long-term management of the Class-A property MorningStar Senior Living recapitalized MorningStar at River Oaks, a Class-A, 112-unit assisted-living and memory-care community in Houston, with investor TPG Angelo Gordon U.S. Real Estate. MorningStar co-developed the community (opened 2021) and will continue managing it under a long-term agreement, deepening its relationship with TPG Angelo Gordon. MorningStar’s portfolio spans 38 communities (operating or in development), 5,000+ units across 11 states. (Link)
  14. Tokyo-based Olympus Corporation agreed to acquire Tel Aviv-area VC-backed MedTech company BioProtect Ltd. for $270 million, adding a prostate cancer radiation spacer device to its urology and oncology portfolio Olympus Corporation announced on May 26, 2026 a definitive agreement to acquire Israel-based BioProtect Ltd. (backed by MVM Partners) for $270 million. BioProtect’s Balloon Spacer is an implantable hydrogel that creates a temporary physical barrier between the prostate and rectum during radiation therapy, reducing healthy-tissue exposure and improving treatment precision in prostate cancer — the second most commonly diagnosed cancer in men globally (~1.5 million new cases/year). The deal extends Olympus’ oncology and urology portfolio adjacent to its core endoscopy platform, consistent with its “Innovation-Driven Growth” strategy. (Link)
  15. Bain Capital agreed to sell Australian residential aged-care provider Estia Health to alternative investment firm Stonepeak, exiting an asset it grew from 73 to 93 homes since 2023 Bain Capital signed an agreement to sell Estia Health, one of Australia’s leading residential aged-care providers, to alternative investment firm Stonepeak; financial terms were not disclosed. Bain Capital acquired Estia in December 2023 and, over its hold, grew the business from 73 homes serving ~6,720 residents to 93 homes serving ~9,250 residents, with more than 14,000 employees. The Bain investment was led by Australia-based partners Mike Murphy, Charles Lawson, and Grace Mollard. The transaction is expected to close in late 2026, subject to regulatory approvals. Bain Capital manages approximately $225 billion in assets across its global platform. (Link)
  16. Dallas, Texas-based PE firm Highlander Partners backed the merger of Bucharest-based MONZA-ARES — Romania’s leading private cardiology and complex surgery hospital group — with Brain Institute, the country’s premier private neurosurgery center, to form one of Romania’s leading private hospital operators MONZA-ARES, Romania’s leading private hospital group focused on cardiology and complex surgery, and Brain Institute, the country’s premier private neurosurgery center, announced on May 26, 2026 they are combining operations to create one of Romania’s leading private healthcare platforms. The merged group is backed by Dallas-based private equity firm Highlander Partners (managing over $3 billion in assets), which has held a majority stake in MONZA-ARES since 2019. The expanded group spans cardiology, neurosurgery, ENT, orthopedics, thoracic surgery, general surgery, and gynecology across facilities in Bucharest, Cluj-Napoca, Constanța, Târgu Jiu, Tulcea, and Onești. Brain Institute shareholders are reinvesting into the combined group. Raiffeisen Bank Romania provided acquisition financing. (Link)
  17. Basel, Switzerland-based CDMO CordenPharma (PE: Astorg) to acquire North Augusta, South Carolina- and Shanghai-based peptide API CDMO AmbioPharm, adding ~400 employees and expanding global peptide manufacturing platform across three continents CordenPharma, the Basel-based global CDMO majority-owned by pan-European PE firm Astorg since 2022, announced on May 27, 2026 an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO with facilities in North Augusta, South Carolina and Shanghai, China. AmbioPharm employs approximately 400 people across its two sites and brings SPPS, LPPS, and hybrid peptide synthesis capabilities that complement CordenPharma’s proprietary Tag-Assisted Peptide Synthesis (TAPS). The North Augusta site becomes CordenPharma’s second U.S. peptide facility, adding purification and lyophilization capacity; the Shanghai campus is CordenPharma’s first Asia-based production footprint. The deal gives pharma customers fully U.S.-based or global supply options for complex, long-chain peptide APIs — strategically timed given rising GLP-1 peptide demand. CordenPharma generated €960 million in sales and employs more than 3,000 across its 11-site network. AmbioPharm shareholders will reinvest into the combined business. (Link)

Venture Deals and Other

  1. Garner Health, a digital care-navigation platform for employers, closed a $100 million Series E at a $2.74 billion valuation led by Index Ventures, with existing backers Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures Garner Health closed a $100 million Series E led by Index Ventures, with existing investors Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures participating, pushing its valuation to $2.74 billion. The round comes just three months after a $118 million Series D. Index partner Jahanvi Sardana praised Garner for making physician quality measurable via AI. The startup, which uses 60 billion-plus medical records to rank providers and steers ~2.5 million members across nearly 800 clients to high performers, will fund its provider-quality platform, AI product development, and member expansion. (Link)
  2. Healthcare data platform H1 secured a $40 million round led by CVS Health Ventures, the corporate venture arm of CVS Health (NYSE: CVS), validating that profitable, data-centric SaaS startups can still attract capital H1, a nine-year-old healthcare data platform that sells detailed physician information to pharma, hospital systems, and insurers, secured $40 million led by CVS Health Ventures, the corporate VC arm of CVS Health (NYSE: CVS). CEO Ariel Katz said H1 wasn’t seeking capital — the company turned cash-flow and EBITDA profitable last year and projects 40%+ growth — but found partnering with a major healthcare player compelling. H1 was last valued at $750 million in a 2021 round led by Altimeter Capital, and acquired Veda and Ribbon Health and grown. (Link)
  3. San Diego-based ClearNote Health closed a $52 million Series D — led by founding investor Mattias Westman — to scale its blood-based early detection tests for pancreatic and ovarian cancer, bringing total funding to $185 million+ ClearNote Health closed a $52 million Series D on May 27, 2026, led by founding investor Mattias Westman with participation from former Citigroup CEO Sandy Weill, Stanford co-founder Dr. Stephen Quake, and institutional investors, bringing total funding to more than $185 million. ClearNote’s Avantect tests use multiomic blood analysis and machine learning to detect pancreatic and ovarian cancers at early stages — two cancers with very limited detection options and poor late-stage survival rates. The company’s multi-cancer detection test was selected for the NCI’s Vanguard Study. Kevin Keegan — formerly GM of Oncology at Illumina and senior leader at BD and Hologic — joined as President and COO alongside the close. (Link)
  4. Oncology-AI startup Triomics raised $22 million in Series B funding led by Battery Ventures, with returning backers Nexus Venture Partners, Lightspeed, and Y Combinator, to bring oncology-specific AI to cancer centers Triomics raised $22 million in a Series B led by Battery Ventures, with returning investors Nexus Venture Partners, Lightspeed, and Y Combinator participating. Founded in 2021, the startup builds oncology-specific AI to automate data-heavy tasks like clinical-trial matching, patient summaries, and tumor-registry reporting; it previously raised a $15 million Series A in mid-2024. Co-founder Sarim Khan said models trained on oncology data win institutions like Memorial Sloan Kettering and Yale Cancer Center over generic scribes such as Abridge and Microsoft’s Nuance. Triomics grew its enterprise base fourfold and recurring revenue tenfold over the past year. (Link)
  5. Silicon Valley metabolic-health startup Signos raised $20 million — with Dexcom (NASDAQ: DXCM), Blue Cross Blue Shield of Alabama, and GV (Google Ventures) participating — to expand its FDA-cleared continuous glucose monitoring platform for weight management Signos raised $20 million to scale its glucose-monitoring platform for weight loss, with Dexcom (NASDAQ: DXCM), Blue Cross Blue Shield of Alabama, and GV (Google Ventures) participating; the round brings total funding to $57 million since 2018. Signos pairs Dexcom’s over-the-counter Stelo sensor with an AI-powered app delivering personalized diet and lifestyle guidance. Investors view it as complementary to GLP-1 drugs, helping users sustain results through behavior change. CEO Sharam Fouladgar-Mercer said the company is targeting self-insured employers as its primary growth channel as it deploys the new capital. (Link)
  6. Plano, Texas-based Secretome Therapeutics closed a $30 million Series A — with RA Capital Management as the sole investor — to advance STM-01, an nCPC-derived therapy for Duchenne muscular dystrophy cardiomyopathy, into pivotal trials Secretome Therapeutics closed a $30 million Series A on May 27, 2026 with RA Capital Management as the sole investor. Proceeds advance STM-01, a therapy derived from neonatal cardiac progenitor cells (nCPCs) targeting Duchenne muscular dystrophy-associated cardiomyopathy — a leading cause of mortality in DMD patients with very few disease-modifying treatment options. The company intends to move STM-01 into pivotal Phase 2 and Phase 3 development. DMD affects approximately 1 in 3,500–5,000 male births globally. RA Capital’s sole-investor structure signals exceptional conviction in the program’s differentiated biology. Former Ra Pharmaceuticals CFO David Lubner joined the Board alongside the close. (Link)
  7. New York-based Solstice, an AI-native pharma commercialization platform, raised $21 million in Series A funding led by Transformation Capital — with Twelve Below and Virtue Ventures participating — to accelerate MLR review compression from months to days Solstice raised $21 million in Series A financing announced May 28, 2026, led by Transformation Capital with Twelve Below, Virtue Ventures, and others, bringing total funding to approximately $25 million. Biopharma companies spend more than $100 billion annually on commercialization, yet medical, legal, and regulatory (MLR) review cycles can stretch three months for routine marketing assets. Solstice compresses that timeline to under 10 days through AI-native content creation, automated regulatory review, fair balance scoring, and performance tracking in a single compliant workflow. The company already serves over a dozen pharma brands including several top-20 global names. (Link)
  8. Boston-based sleep-tech startup SOND exited stealth with $7 million from E14 Fund, Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele to launch its closed-loop Dreambuds sleep earbuds SOND, founded by MIT grads including Bose’s former Head of Global Sleep Yadid Ayzenberg, emerged from stealth with $7 million from E14 Fund (MIT-affiliated), Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele. The funding accompanies its debut product, Dreambuds — closed-loop in-ear devices capturing 12 physiological signals and feeding a cloud-based AI sleep coach. SOND aims for mass production by Q2 2026 following a planned crowdfunding campaign, and is currently taking reservations. (Link)
  9. New York-based Kubera Health raised $6.5 million in seed funding led by Upfront Ventures — with Company Ventures, Dria Ventures, and SemperVirens participating — to build the contract-to-payment infrastructure layer for U.S. healthcare Kubera Health raised $6.5 million in seed funding announced May 28, 2026, led by Upfront Ventures with Company Ventures, Dria Ventures, and SemperVirens participating. Founded by physician-executive Roja Garimella, MD, MBA, Kubera is building the contract-to-payment system of record for American healthcare — translating complex payor-provider contracts and fee schedules into structured, continuously auditable logic running against claims and payment data in real time. The AMA estimates one in five commercial claims is processed inaccurately, contributing to roughly $1 trillion in annual administrative burden. Early enterprise customers including Hollywood Presbyterian Medical Center have expanded their engagements. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities

CLICK HERE

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)